Etrasimod

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 142 publications

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus.

Journal: Journal of Crohn's & colitis

Published: May 20, 2026

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Small Molecules as Advanced Therapy for the Treatment of Inflammatory Bowel Disease, Particularly Regarding Ulcerative Colitis.

Journal: Internal medicine (Tokyo, Japan)

Published: May 17, 2026

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Efficacy and Safety of Etrasimod in Moderate-To-Severe Ulcerative Colitis: A GRADE-Based Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Journal: The Annals of pharmacotherapy

Published: March 27, 2026

Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients with Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis with Meta-regression.

Efficacy of Biological and Steroid Therapies in Adolescent and Adult Patients with Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis with Meta-regression.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: February 03, 2026

Etrasimod: A Next-Generation S1P Receptor Modulator for Ulcerative Colitis - Mechanistic Insights and Clinical Progress.

Etrasimod: A Next-Generation S1P Receptor Modulator for Ulcerative Colitis - Mechanistic Insights and Clinical Progress.

Journal: Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology

Published: February 03, 2026

Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn's Disease.

Etrasimod Treatment Modulates Circulating and Lymph Node-Derived Lymphocytes in Crohn's Disease.

Journal: International journal of molecular sciences

Published: January 21, 2026

Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds.

Expanding the therapeutic horizon in inflammatory bowel disease: The rise of non-cytokine compounds.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 12, 2026

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

Effectiveness of etrasimod on disease activity and patient-reported outcomes in ulcerative colitis-EFFECT-UC: a non-interventional, multinational, prospective cohort study protocol.

Journal: BMJ open

Published: December 25, 2025

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial.

The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 22, 2025

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease.

Journal: Journal of gastroenterology and hepatology

Published: December 13, 2025

Autotaxin Induces S1P/S1PR1 Signaling to Affect Th17/Treg Cell Balance and Exacerbate Intestinal Inflammation in Colitis.

Autotaxin Induces S1P/S1PR1 Signaling to Affect Th17/Treg Cell Balance and Exacerbate Intestinal Inflammation in Colitis.

Journal: International journal of molecular sciences

Published: December 04, 2025

Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Sphingosine 1-Phosphate (S1P) Receptor Modulators as an Induction and Maintenance Therapy for Moderate to Severe Ulcerative Colitis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

Journal: Digestive diseases and sciences

Published: December 02, 2025

Showing 1-12 of 142

Last Updated: 06/30/2026